Associate Professor, Psychiatry, Yale University School of Medicine
Psychiatry
Dr. Deepak C. D'Souza, MD
|
|
Give Review
Deepak C. D'Souza works in the field of Psychiatry. He researched medicine at St. John's Medical College. Deepak D'Souza is a published physician as well. He has 87 publications published. The latest was: D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia.
Publications
- Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis.
- Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.
- The early identification of psychosis: can lessons be learnt from cardiac stress testing?
- Marijuana Legalization: Impact on Physicians and Public Health.
- GABA Deficit Enhances the Psychotomimetic Effects of Δ(9)-THC.
- Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia: A Positron Emission Tomographic Functional Magnetic Resonance Imaging Study.
- Δ(9)-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.
- Medicalization of marijuana--reply.
- Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users.
- Impact of Cannabis Use on the Development of Psychotic Disorders.
- Problems with the medicalization of marijuana.
- Testing differences in the activity of event-related potential sources: Important implications for clinical researchers.
- Effects of Δ(9)-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism.
- In Vivo Evidence for β2 Nicotinic Acetylcholine Receptor Subunit Upregulation in Smokers as Compared with Nonsmokers with Schizophrenia.
- Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia.
- Spicing things up: synthetic cannabinoids.
- The Impact of NMDA Receptor Blockade on Human Working Memory-Related Prefrontal Function and Connectivity.
- Acute effects of THC on time perception in frequent and infrequent cannabis users.
- Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.
- Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.
- Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study.
- Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies.
- Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans.
- Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia.
- Cannabinoids, working memory, and schizophrenia.
- Naltrexone does not attenuate the effects of intravenous ??9-tetrahydrocannabinol in healthy humans.
- Lower ?2*-Nicotinic Acetylcholine Receptor Availability in Smokers With Schizophrenia.
- Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence.
- Glutamatergic Modulation of Auditory Information Processing in the Human Brain.
- Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dep...
- Probing GABA receptor function in schizophrenia with iomazenil.
- Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
- Capgras syndrome induced by ketamine in a healthy subject.
- Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.
- Cannabinoids and psychosis.
- Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia.
- Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.
- gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation.
- Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
- Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.
- Gone to Pot - A Review of the Association between Cannabis and Psychosis.
- The safety of studies with intravenous Δâ¹-tetrahydrocannabinol in humans, with case histories.
- [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].
- Cannabis and psychosis/schizophrenia: human studies.
- Modelling psychosis.
- Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.
- Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.
- The effects of cannabinoids on serum cortisol and prolactin in humans.
- The acute effects of cannabinoids on memory in humans: a review.
- Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.
- Greater vulnerability to the amnestic effects of ketamine in males.
- Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine.
- Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II ...
- Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.
- IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans.
- Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.
- Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions.
- NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.
- Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B...
- Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia sym...
- Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients.
- Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale.
- Psychiatric safety of ketamine in psychopharmacology research.
- Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients.
- Nicotine effects on brain function and functional connectivity in schizophrenia.
- NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
- Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D(2) receptor".
- The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.
- Symptom provocation studies in psychiatric disorders: scientific value, risks, and future.
- The NMDA antagonist model for schizophrenia: promise and pitfalls.
- Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitiv...
- Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.
- Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.
- Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.
- N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability.
- D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia.
- NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
- Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders.
- Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
- An examination of cancer patients'' monthly ''out-of-pocket'' costs in Ontario, Canada.
- Cannabinoid antagonists: a treatment in search of an illness.
- Lower prolactin bioactivity in unmedicated schizophrenic patients.
- Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans.
- Marijuana and Madness: Associations Between Cannabinoids and Psychosis.
- Human Laboratory Studies on Cannabinoids and Psychosis.
Schools
St John39s Medical College Rajiv Gandhi University Of Health Sciences
Doctors Specialties
- Psychiatry
Accepted Insurances
Education
-
SUNY Health Science Center at Brooklyn -
St. John's Medical College
Helpful Reviews
Similar Doctors
|
|
Dr. Susan D. Kruger, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erika Jessen, MD |
|
|
Dr. Robert A. Rosenheck, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ismene Petrakis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne M. Carroll, MD |
|
|
Dr. Rachel B. Katz, MD |
|
|
Dr. Mohini Ranganathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mehmet Sofuoglu, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|